Results 61 to 70 of about 18,455 (220)
Potentiation of peptide receptor radionuclide therapy by the PARP inhibitor olaparib [PDF]
, 2016 Metastases expressing tumor-specific receptors can be targeted and treated by binding of radiolabeled peptides (peptide receptor radionuclide therapy or PRRT).
Beerens, C.E.M.T. (Cecile) +7 more
core +1 more source
Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements
Cancers, 2023 Neuroendocrine neoplasms (NENs) are tumors originating from neuroendocrine cells distributed throughout the human body. With an increasing incidence over the past few decades, they represent a highly heterogeneous group of neoplasms, mostly expressing somatostatin receptors (SSTRs) on their cell surface. Peptide receptor radionuclide therapy (PRRT) has
Elettra Merola, Chiara Maria Grana
openaire +3 more sources
Advanced Science, EarlyView.Our study reveals a novel mechanism of a positive regulatory circuit between Cav1.2 and H3K27ac for pancreatic neuroendocrine neoplasms (pNENs) progression. Cav1.2 is identified as a crucial target for promoting disease progression and correlates with malignant behaviors, which are remarkably inhibited by the administration of calcium channel blockers (
Yangyinhui Yu +12 more
wiley +1 more source
Preclinical animal research on therapy dosimetry with dual isotopes [PDF]
, 2011 Preclinical research into radionuclide therapies based on radiation dosimetry will enable the use of any LET-equivalent radionuclide. Radiation dose and dose rate have significant influence on dose effects in the tumour depending on its radiation ...
Mark W. Konijnenberg, Marion de Jong
core +4 more sources
The next generation of peptide receptor radionuclide therapy [PDF]
Endocrine-Related Cancer, 2019 Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-[Tyr3]octreotate has been successfully developed in the last decades for the treatment of neuroendocrine neoplasms. However, different methods to improve the objective response rate and survival are under investigation.
Brabander, Tessa +2 more
openaire +3 more sources
GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy
Advanced Science, EarlyView.Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu +11 more
wiley +1 more source
Archives of Endocrinology and MetabolismSUMMARY Hemangioblastomas associated with von Hippel-Lindau (VHL) disease are frequently multiple and recur during prolonged follow-up. Currently, no systemic treatment is available for these tumors.
Eloá Pereira Brabo +4 more
doaj +1 more source
Endocrinology, Diabetes & Metabolism Case Reports, 2022 Acanthosis nigricans (AN) is a common dermatosis associated with hyperinsulinemia and insulin resistance. However, AN has been rarely reported in patients with insulinoma, a state of persistent hyperinsulinemia. We present a case of metastatic insulinoma,
Jenny S W Yun +3 more
doaj +1 more source
Immunoscintigraphy for therapy decision making and follow-up of biological therapies [PDF]
, 2016 With the availability of new biological therapies there is the need of more accurate diagnostic tools to noninvasively assess the presence of their targets.
Auletta, S. +6 more
core +2 more sources
Natural History and Management of Familial Paraganglioma Syndrome Type 1: Long-Term Data from a Large Family [PDF]
, 2020 Head and neck paragangliomas are the most common clinical features of familial paraganglioma syndrome type 1 caused by succinate dehydrogenase complex subunit D (SDHD) mutation. The clinical management of this syndrome is still unclear.
Cantisani, Vito +12 more
core +1 more source